OverviewSuggest Edit
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
| Type | Public | |
| Founded | 1978 | |
| HQ | Cambridge, MA, US | Map |
| Website | biogen.com | |
| Employee Ratings | More | |
| Overall Culture | A- | More |
Recent NewsAll News
- Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others
- Worldwide Neuralgia Treatment Industry to 2027 - Players Include Allergan, GlaxoSmithKline & Biogen Among Others
- Insights on the Alzheimer's Disease Drugs Global Market to 2027 - Featuring Allergen, Biogen and Genentech Among Others
- Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Key People/Management at Biogen
Michel Vounatsos
Chief Executive Officer and Director
Stelios Papadopoulos
Chairman of the Board
Alisha Alaimo
President, Biogen U.S. Organization
Johanna Friedl-Naderer
President, Europe, Canada & Partner Markets
Alexander J. Denner
Director and Chair, Corporate Governance Committee
Rachid Izzar
President, Biogen Intercontinental Region
Biogen Office Locations
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
601 Pennsylvania Ave NW #720
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $13.44 b in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 13.4b |
Gross profit (FY, 2020) | 11.6b |
Gross profit margin (FY, 2020), % | 86.6% |
Net income (FY, 2020) | 4.1b |
EBIT (FY, 2020) | 4.6b |
Market capitalization (5-Apr-2021) | 42.3b |
Closing stock price (5-Apr-2021) | 277.9 |
Cash (31-Dec-2020) | 1.3b |
EV | 48.4b |
Biogen's current market capitalization is $42.3 b.
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.8b | 3.1b | 3.1b | 3.1b | 3.4b | 3.4b | 3.5b | 3.6b | 3.6b | 3.5b | 3.7b | 3.4b |
Cost of goods sold | 384.6m | 366.2m | 370.0m | 446.0m | 421.0m | 460.8m | 602.0m | 476.3m | 430.0m | 454.3m | 411.1m | 449.1m |
Gross profit | 2.4b | 2.7b | 2.7b | 2.7b | 2.9b | 3.0b | 2.9b | 3.1b | 3.2b | 3.1b | 3.3b | 2.9b |
Gross profit Margin, % | 86% | 88% | 88% | 86% | 87% | 87% | 83% | 87% | 88% | 87% | 89% | 87% |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 924.0m | 1.2b | 1.5b | 4.1b | 1.3b | 2.4b | 2.2b | 1.7b | 2.3b | 2.6b | 2.4b | 2.2b |
Accounts Receivable | 1.5b | 1.6b | 1.6b | 1.9b | 2.0b | 2.0b | 2.1b | 2.0b | 1.9b | 2.1b | 2.1b | 2.0b |
Inventories | 921.6m | 936.5m | 1.0b | 890.8m | 931.7m | 916.6m | 770.2m | 776.7m | 751.8m | 858.8m | 952.7m | 1.0b |
Current Assets | 6.9b | 7.1b | 7.6b | 10.2b | 7.4b | 8.7b | 8.9b | 7.9b | 8.4b | 8.0b | 8.5b | 7.8b |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 747.5m | 1.6b | 2.8b | 1.2b | 2.1b | 3.5b | 1.4b | 2.9b | 4.4b | 1.4b | 3.0b | 3.7b |
Depreciation and Amortization | 512.0m | 814.6m | 992.0m | 168.9m | 340.4m | 686.9m | 121.1m | 238.1m | 567.6m | 119.9m | 232.8m | 366.8m |
Inventories | (46.2m) | (85.3m) | (170.3m) | (2.6m) | (40.1m) | (31.9m) | (129.0m) | (108.7m) | (47.3m) | (62.2m) | (188.2m) | (270.6m) |
Cash From Operating Activities | 235.2m | 1.4b | 3.0b | 1.5b | 2.6b | 4.3b | 1.5b | 3.4b | 5.1b | 1.5b | 3.4b | 4.6b |
| USD | Q1, 2017 |
|---|---|
Debt/Equity | 0.6 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.8 x |
Biogen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Nightstar Therapeutics | March 04, 2019 | $800 m |
| AliveGen | July 25, 2018 | $27.5 m |
| Karyopharm Therapeutics | January 25, 2018 | $10 m |
| Remedy Pharmaceuticals | May 18, 2017 | $120 m |
| Convergence Pharmaceuticals | February 14, 2014 | $675 m |
| Stromedix | February 14, 2014 | $75 m |
| Tysabri | February 28, 2013 | |
| Syntonix Pharmaceuticals | January 04, 2007 | $120 m |
| Fumapharm | May 31, 2006 | |
| Conforma Therapeutics | May 03, 2006 | $150 m |
Biogen Revenue Breakdown
Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other
Biogen Cybersecurity Score
Biogen Environment, Social & Governance (ESG) Ratings
Biogen Online and Social Media Presence
37.73k Twitter followers
Biogen has 37.73k Twitter Followers. The number of followers has increased 0.8% month over month and increased 2.4% quarter over quarter
Biogen's Trends
Twitter Engagement Stats for @biogen
4.9k
Tweets
252
Following
37.7k
Followers
21
Tweets last 30 days
19.9
Avg. likes per Tweet
100%
Tweets with engagement
Biogen Company Culture
Overall Culture
A-
78/100
CEO Rating
B
72/100
Compensation
A+
88/100
Diversity
A
80/100
Biogen News and Updates
April 01, 2021
Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others
Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
March 19, 2021
Worldwide Neuralgia Treatment Industry to 2027 - Players Include Allergan, GlaxoSmithKline & Biogen Among Others
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global neuralgia treatment market size is pred…
March 12, 2021
Insights on the Alzheimer's Disease Drugs Global Market to 2027 - Featuring Allergen, Biogen and Genentech Among Others
DUBLIN, March 12, 2021 /PRNewswire/ -- The "Alzheimer's Disease Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Alzheimers Disease Drugs estimated at US$ 5.9 Billion in the year 2020,...
March 04, 2021
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple the…
February 24, 2021
Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake
If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.
February 24, 2021
Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Life Science Cares Boston and the Biogen Foundation have teamed up as inaugural sponsors of Food For Free’s new Just Eats Grocery Box program, a $170,000 effort to reduce food insecurity for 3,000 area families, starting this month. To launch Jus…
Biogen Blogs
April 12, 2021
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb
April 09, 2021
Biogen Announces Two New Nominees for Election to Board of Directors
Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.
April 09, 2021
Biogen to Report First Quarter 2021 Financial Results April 22, 2021
Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2021 financial results Thursday, April 22, 2021, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.
March 22, 2021
Biogen to Participate in the Stifel 3rd Annual CNS Day
Biogen to Participate in the Stifel 3rd Annual CNS Day
Ray.Beron@west.com
Mon, 03/22/2021 - 12:51
Biogen to Participate in the Stifel 3rd Annual CNS Day
March 22, 2021 at 4:06 PM EDT
This release is a backfill from a News Wire
Investor Re…
March 03, 2021
Biogen to Webcast Aducanumab Presentations from AD/PD 2021 Virtual Conference on March 9-13, 2021
Cambridge, Mass. – Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. AD/PD Webcast Schedule Details: Wednesday,
February 22, 2021
Biogen to Participate in the Cowen 41st Annual Health Care Conference
Biogen to Participate in the Cowen 41st Annual Health Care Conference
joseibrahim.de…
Mon, 02/22/2021 - 10:23
Biogen to Participate in the Cowen 41st Annual Health Care Conference
February 22, 2021 at 4:06 PM EST
This release is a backfill from a News Wire
…
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Alisha Alaimo.
How many employees does Biogen have?
Biogen has 7,400 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $13.4 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.8 m.
Who are Biogen competitors?
Competitors of Biogen include Cassava Sciences, Covance and Sanofi Genzyme.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations.
How many offices does Biogen have?
Biogen has 39 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies